In this framework, the T22-DITOX-H6 nanotoxin represents a promising approach for HNSCC treatment, as it aims to deliver cytotoxic compounds exclusively to CXCR4+ cancer cells. The gene discussed is CXCR4; the disease is head and neck squamous cell carcinoma.